THALLOUS CHLORIDE TL 201

Post-LOE

thallous chloride tl-201

Curium Pharma

ANDAINTRAVENOUSINJECTABLE

Approved

Nov 2006

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

THALLOUS CHLORIDE TL 201 (thallous chloride tl-201) by Curium Pharma is 201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. First approved in 2006.

Drug data last refreshed 20h ago

Mechanism of Action

201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. Experiments in healthy subjects using labeled microspheres have shown that the myocardial distribution of thallous chloride Tl 201 correlates with regional perfusion. In clinical studies, Thallous…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on THALLOUS CHLORIDE TL 201 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.